Status:
COMPLETED
Single Dose Escalation Study of PF-05190457 in Healthy Volunteers
Lead Sponsor:
Pfizer
Conditions:
Diabetes Mellitus, Type II
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
PF-05190457 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The purpose of the study is to evaluate the safety and tolerability of PF-05190457 after administration of a sin...
Eligibility Criteria
Inclusion
- Healthy males and females (non-childbearing) between the ages of 18 and 55 with BMI of 17.5 to 30.5 kg/m2; and a total body weight between 50 kg (110 lbs) and 100 kg (220 lb) inclusive
Exclusion
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease
Key Trial Info
Start Date :
December 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2011
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT01247896
Start Date
December 1 2010
End Date
June 1 2011
Last Update
July 6 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Brussels, Belgium, B-1070